Journal Mobile Options
Table of Contents
Vol. 79, No. 3, 2004
Issue release date: March 2004
Neuroendocrinology 2004;79:157–162

Obesity and Plasma Concentrations of Alpha-Tocopherol and Beta-Carotene in Epileptic Girls Treated with Valproate

Verrotti A. · Greco R. · Latini G. · De Simone M. · Chiarelli F.
aDepartment of Medicine, Section of Pediatrics, University of Chieti, Chieti; bDepartment of Pediatrics, Hospital of Brindisi, Brindisi, and cDepartment of Pediatrics, University of L’Aquila, L’Aquila, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


To investigate whether epileptic patients who become obese after valproic acid (VPA) therapy can have a high risk of atherosclerosis related to the oxidation of low-density lipoprotein, we prospectively studied the plasma concentrations of lipid-soluble antioxidant vitamins in a group of 20 epileptic girls and 20 controls. After 1 year of VPA treatment, epileptic patients who gained weight had decreased plasma concentrations of α-tocopherol and α- and β-carotene, the main lipid-soluble antioxidants. Moreover, 5 patients who gained weight were reevaluated 6 months after withdrawal from VPA therapy and showed normal body mass indices and normalized plasma levels of antioxidants. In conclusion, the data suggest that epileptic patients who gain weight after VPA therapy have reduced plasma concentrations of antioxidant vitamins and that these reductions are reversible after VPA withdrawal.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Biton V, Mirza W, Montouris G: Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;57:565–566.
  2. Jallon P, Picard F: Bodyweight gain and anticonvulsants: A comparative review. Drug Saf 2001;24:969–978.
  3. Verrotti A, Basciani F, Morresi S, De Martino M, Morgese G, Chiarelli F: Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:230–232.
  4. Isojärvi JIT, Astrup A, Gram L: Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579–584.
  5. Kusunoki M, Yamamura T, Ichii S: The effect of sodium valproate on plasma somatostatin and insulin in humans. J Clin Endocrinol Metab 1988;67:1060–1063.
  6. Verrotti A, Basciani F, De Simone M, Trotta D, Chiarelli F: Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002;17:1–4.
  7. Gey KF, Brubacher GB, Stahelin HB: Plasma levels of antioxidant vitamins in relation to ischemic heart disease and cancer. Am J Clin Nutr 1987;45:1368–1377.
  8. Kuno T, Hozumi M, Morinobu T, Murata T, Mingci Z, Tamai H: Antioxidant vitamin levels in plasma and low density lipoprotein of obese girls. Free Rad Res 1997;28:81–86.
  9. Wallström P, Wirfält E, Lahamann PH, Gulberg B, Janzon L, Berghund G: Serum concentrations of β-carotene and α-tocopherol are associated with diet, smoking, and general and central adiposity. Am J Clin Nutr 2001;73:777–785.
  10. Decsi T, Molnar D, Koletzko B: Reduced plasma concentrations of alpha-tocopherol and beta-carotene in obese boys. J Pediatr 1997;130:653–655.
  11. Esterbauer H, Dieber-Rotheneder M, Striegl G, Waeg G: Role of vitamin E in preventing the oxidation of low-density lipoprotein. Am J Clin Nutr 1991;53:314–321.
  12. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989;30:389–399.
  13. Verrotti A, Domizio S, Angelozzi B, Sabatino G, Morgese G, Chiarelli F: Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health 1997;33:242–245.
  14. Göbel Y, Schaffer C, Koletzko B: Simultaneous determination of low plasma concentrations of retinol and tocopherols in preterm infants by a HPLC micromethod. J Chromatogr, in press.
  15. Thurnham DI, Davies JA, Crump BJ, Situnayake RD, Davis M: The use of different lipids to express serum tocopherol: Lipid ratios for the measurement of vitamin E status. Ann Clin Biochem 1986;23:514–520.
  16. Borgos AM, Wartanowicz M, Ziemlanski S: Blood vitamin and lipid levels in overweight and obese women. Eur J Clin Nutr 1992;46:803–808.
  17. Barker DJP, Winter PD, Osmond C: Weight in infancy and death from ischaemic heart disease. Lancet 1989;ii:557–580.
  18. Barker DJP, Bull AR, Osmond C, Simmond SJ: Fetal and placental size and risk of hypertension in adult life. BMJ 1990;301:259–262.
  19. Lillioia S, Nyomba BL, Saad MF: Exaggerated early insulin release and insulin resistance in diabetes-prone population: A metabolic comparison of Pima Indians and Caucasian. J Clin Endocrinol Metab 1991;73:866–876.
  20. Saad MF, Knowler WC, Pettitt DJ: A two-step model for development of noninsulin dependent diabetes. Am J Med 1991;90:229–235.
  21. Haffner SM, Stern MP, Hazuda HP: Increased insulin concentrations in nondiabetic offspring of diabetic parents. N Engl J Med 1988;319:1297–1301.
  22. Charles MA, Fontbonne A, Thibult N: Risk factors for NIDDM in white population: Paris prospective study. Diabetes 1991;40:796–799.
  23. Bergman RN: Towards physiological understanding of glucose tolerance – minimal model approach. Diabetes 1989;38:1512–1527.
  24. Bergman RN, Steil GM, Bradley DC, Watanabe RM: Modeling of insulin action in vivo. Annu Rev Physiol 1992;54:861–883.
  25. Verrotti A, Basciani F, Domizio S, Sabatino G, Morgese G, Chiarelli F: Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol 1998;19:364–367.
  26. Heldenberg D, Harel S, Holtzman M, Levtow O, Tamir I: The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children. Neurology 1983;33:510–512.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50